Austin M. Day
Associate | Charlotte
Austin M. Day

Austin M. Day represents a diverse range of clients in public and private securities offerings of equity and debt, including venture capital and growth stage preferred stock and convertible note financings, initial public offerings, follow-on public offerings, PIPEs, “at-the-market” offerings and notes offerings. Mr. Day also counsels clients on corporate governance, periodic reporting and securities regulation and general corporate matters.

  • MSC Income Fund, a business development company, in connection with its US$92.6 million public offering of common stock and listing on the New York Stock Exchange.
  • Main Street Capital Corporation, a business development company, in connection with its underwritten public offerings of US$350 million of notes, US$300 million of notes and US$100 million of notes.
  • AB Private Credit Investors in connection with the formation and launch of AB Private Lending Fund, a publicly offered non-traded business development company.
  • Aquestive Therapeutics, a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, in connection with its US$75 million underwritten public offering of common stock.
  • vTv Therapeutics, a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates, in connection with its US$51 million private placement financing of common stock and pre-funded warrants.
  • PaxMedica, Inc., a biopharmaceutical company focused on advancing treatments for neurological disorders, in connection with its US$7 million public offering of common stock and warrants.
  • Raymond James & Associates, in connection with Fidus Investment Corporation’s US$300 million “at-the-market” facility.
  • Graham Partners, in connection with its Series A and Series B investments in Novarc Technologies Inc., a full-stack robotics company.
  • Janux Therapeutics, Inc., a biopharmaceutical company, in connection with its US$194.0 million initial public offering, US$125.0 million Series B Preferred Stock financing and US$56.0 million Series A Preferred Stock financing.
  • Allogene Therapeutics, Inc., an immuno-oncology company, in connection with its US$372.6 million initial public offering and US$300.0 million Series A and Series A-1 Preferred Stock financing.
  • Synthorx, Inc., a biopharmaceutical company, in connection with its US$150.7 million initial public offering and US$63.0 million Series C Preferred Stock financing.
  • Kura Oncology, Inc., a biopharmaceutical company, in connection with its US$115.3 million, US$143.9 million and US$345.1 million follow-on underwritten public offerings.
  • Regulus Therapeutics Inc., a biopharmaceutical company, in connection with PIPE transactions for US$41.5 million, US$19.4 million and US$34.6 million.

Includes matters handled at Dechert or prior to joining the firm.

Services Industries
    • The University of Utah, B.A., 2013, summa cum laude
    • Brigham Young University, J.D., 2016, magna cum laude, Order of the Coif, BYU Law Review
    • North Carolina
    • California